Ile-Pro-Pro attenuates sympathetic activity and hypertension

Area of Science:

• Cardiovascular Physiology
• Neuropeptide Research
• Hypertension Therapeutics

Background:

• Isoleucine-proline-proline (IPP) is a food-derived tripeptide known to inhibit angiotensin-converting enzyme (ACE).
• Sympathetic overactivity and oxidative stress are key contributors to hypertension.
• Understanding the central and peripheral actions of IPP is crucial for its therapeutic potential.

Purpose of the Study:

• To investigate the roles of IPP in modulating sympathetic activity, oxidative stress, and hypertension.
• To determine the mechanisms underlying IPP's effects in both the central nervous system and peripheral circulation.

Main Methods:

• Induction of renovascular hypertension in Sprague-Dawley rats using the two-kidney one-clip (2K1C) model.
• Direct microinjections of IPP into the hypothalamic paraventricular nucleus (PVN) and intravenous administration.
• Measurement of renal sympathetic nerve activity, blood pressure, and assessment of ACE activity and oxidative stress markers.

Main Results:

• Central (PVN) and peripheral (intravenous) administration of IPP significantly attenuated sympathetic activity and blood pressure in 2K1C rats.
• IPP inhibited ACE activity and reduced superoxide production in the PVN and arteries.
• Long-term intraperitoneal IPP treatment improved hypertension, vascular remodeling, and oxidative stress.

Conclusions:

• IPP effectively attenuates hypertension and sympathetic activity through inhibition of ACE and oxidative stress.
• The sympathoinhibitory effects of peripheral IPP are primarily mediated by ACE inhibition within the PVN.
• IPP demonstrates therapeutic potential for hypertension, impacting both central and peripheral mechanisms and reducing vascular damage.